Author:
Holowiecki J.,Krzemien S.,Kuratowska Z.,Hellmann A.,Krykowski E.,Dmoszyñska A.,Skotnicki A.,Konopka L.,Maj S.,Rudzka E.,Krawcyzk M.,Holowiecka B.
Publisher
Springer Berlin Heidelberg
Reference19 articles.
1. Berman E, McBride M. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 1992; 79: 3267–3273.
2. Robert J, Rigal-Huguet F, Hurterloup P. Comparative pharmacokinetic study of idarubicin and daunorubicn in leukemia patients. Hematol-Oncol. 1992; 10: 111–116.
3. Kuffel MJ, Reid JM, Ames MM. Anthracydines and their c-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture. Cancer Chemother. Pharmacol. 1992; 30: 51–57.
4. Berman E, Heller G, Santorsa J, McKenzie S, Gee T, Kempin S, Gulati S, Andreef M, Kolitz J, Gabrilove J. Results of a randomized trial comparing idarubicin and cytosine arabinoside with newly diagnosed acute myelogenous leukemia. Blood 1991; 77: 1666–1674.
5. Carella AM, Carlier P, Pungolino E, Resegotti L, Liso V, Stasi R, Montillo M, Iacopino P, Mitro S, Pagano L. Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. The GIMEMA Cooperative Group. Leulemia 1993; 7: 196–199.